BioParity.UFO / UAP research

58 sources for “Garry Nolan research”

Results

PaperS7587

DRUG-NEM: Optimizing drug combinations using single-cell perturbation response to account for intratumoral heterogeneity

Benedict Anchang, Kara L. Davis, Harris G. Fienberg, Brian D. Williamson, Sean C. Bendall, Loukia G. Karacosta, Robert Tibshirani, Garry P. Nolan, Sylvia K. Plevritis. ebi.ac.uk. April 13, 2018.

DRUG-NEM ranks drug combinations using selected single-cell signaling responses. Its short-term surrogates and fixed-subpopulation assumptions limit interpretation. Repeated analyses are not new patients, and cell-line validation does not establish clinical benefit. The supplied main text is read; supporting information remains missing.

Supplied main text and mathematics read; apparatus partial
PaperS7500

Single-cell mass cytometry reveals distinct populations of brain myeloid cells in mouse neuroinflammation and neurodegeneration models

Bahareh Ajami, Nikolay Samusik, Peter Wieghofer, Peggy P. Ho, Andrea Crotti, Zach Bjornson, Marco Prinz, Wendy J. Fantl, Garry P. Nolan, Lawrence Steinman. med.stanford.edu. March 5, 2018.

Ajami, Nolan and colleagues analyse brain myeloid populations in mouse disease models. Mouse treatment findings do not establish human therapy or UAP-related illness. Pooling, statistical assumptions and inconsistencies constrain interpretation.

Paper, methods, figures and checklist read
PaperS7593

Commonly Occurring Cell Subsets in High-Grade Serous Ovarian Tumors Identified by Single-Cell Mass Cytometry

Veronica D. Gonzalez, Nikolay Samusik, Tiffany J. Chen, Erica S. Savig, Nima Aghaeepour, David A. Quigley, Ying-Wen Huang, Valeria Giangarrà, Alexander D. Borowsky, Neil E. Hubbard, Shih-Yu Chen, Guojun Han, Alan Ashworth, Thomas J. Kipps, Jonathan S. Berek, Garry P. Nolan, Wendy J. Fantl. ebi.ac.uk. February 13, 2018.

Mass cytometry identifies tumor-cell subsets and outcome associations in a small ovarian-cancer cohort. Dominant and hybrid clusters did not individually correlate with relapse. Same-cohort marker selection and missing independent validation limit interpretation; cell-line response is not demonstrated patient benefit.

Supplied author manuscript read; figures and supplement missing
PaperS7577

An immune clock of human pregnancy

Nima Aghaeepour, Edward A. Ganio, David Mcilwain, Amy S. Tsai, Martha Tingle, Sofie Van Gassen, Dyani K. Gaudilliere, Quentin Baca, Leslie McNeil, Robin Okada, Mohammad S. Ghaemi, David Furman, Ronald J. Wong, Virginia D. Winn, Maurice L. Druzin, Yaser Y. El-Sayed, Cecele Quaintance, Ronald Gibbs, Gary L. Darmstadt, Gary M. Shaw, David K. Stevenson, Robert Tibshirani, Garry P. Nolan, David B. Lewis, Martin S. Angst, Brice Gaudilliere. ebi.ac.uk. September 1, 2017.

An observational immune model tracks term-pregnancy chronology in18 training and10 validation participants. Performance falls in validation; preterm pregnancies were excluded. Correlations do not establish causal immune mechanisms or preterm prediction. Source value, demographic and metadata conflicts accompany missing original article layouts and raw data. Nolan assisted interpretation and writing and disclosed equity interests.

Complete supplied main text and11-page supplement read; original main PDF and raw gaps
PaperS7574

Reversibility of Defective Hematopoiesis Caused by Telomere Shortening in Telomerase Knockout Mice

Aparna Raval, Gregory K. Behbehani, Le Xuan Truong Nguyen, Daniel Thomas, Brenda Kusler, Alina Garbuzov, John Ramunas, Colin Holbrook, Christopher Y. Park, Helen Blau, Garry P. Nolan, Steven E. Artandi, Beverly S. Mitchell. journals.plos.org. July 2, 2015.

Selected mouse experiments report recovery of blood and cell readouts after telomerase reactivation, while finding no measurable telomere-length increase. Proposed explanations and a leukemia model remain separate from observations. Native cell-label, genotype, caption and statistical-bound conflicts persist. Nolan contributed analysis and tools and disclosed an instrument-manufacturer financial interest.

Defined supplied article and static apparatus read; raw and Word-layout gaps
PaperS7558

Mass cytometry as a platform for the discovery of cellular biomarkers to guide effective rheumatic disease therapy

Nitya Nair, Henrik E. Mei, Shih-Yu Chen, Matthew Hale, Garry P. Nolan, Holden T. Maecker, Mark Genovese, C. Garrison Fathman, Chan C. Whiting. ebi.ac.uk. May 18, 2015.

This 2015 review discusses mass cytometry as a possible aid to rheumatic-disease research. Its preliminary illustration compares one patient with one healthy control; concurrent treatment and assay timing limit interpretation. The authors explicitly consider residual drug neutralizing added TNF as an alternative to changed cell signaling. The illustration does not establish a validated biomarker or clinical recommendation. Nolan is a verified coauthor, while detailed individual contribution roles are not supplied.

Complete supplied review text and figures read
PaperS7579

Early reprogramming regulators identified by prospective isolation and mass cytometry

Ernesto Lujan, Eli R. Zunder, Yi Han Ng, Isabel N. Goronzy, Garry P. Nolan, Marius Wernig. ebi.ac.uk. April 1, 2015.

A mouse-cell study associates early reprogramming with a transient marker state, while showing that marker usefulness changes with time and model. Bulk colonies and unique reprogramming events are different outcomes. Limited replication, negative controls and speculative human extension remain explicit. The supplied manuscript text is read; full diagrams, tables and publisher corrections remain incomplete.

Complete supplied manuscript text read; meaningful apparatus partial
ReportS7680

FDA contract listing — selected Stanford award 75F40120C00176

U.S. Food and Drug Administration. fda.gov.

An FDA contract listing names Stanford University for 75F40120C00176, independently of the MaxFuse acknowledgement. The requirement concerns coronavirus research. Its wording differs from a later FDA presentation using the same identifier; the amendment or naming history remains unresolved. This supports a public institutional funding link, without establishing Nolan as the named principal investigator or a classified programme.

Partial root native PDF text and selected layout review
ReportS7708

NIH RePORTER metadata for 3U19AI100627-09S2

National Institutes of Health. api.reporter.nih.gov.

Official NIH metadata returns two FY2021 application records for 3U19AI100627-09S2, both naming Scripps as recipient and the same amount. Their contact PIs are Garry P. Nolan and Richard J. Ulevitch; Sage appears in neither PI list. Shared identifiers and differing dates do not establish two independent awards or their administrative relationship. The paper’s Sage/Nolan support acknowledgement is preserved as a different fact from registered PI metadata. No classified approach, agency adoption or UAP involvement is established.

Official award metadata only; scientific and award bodies unreviewed

A curated public selection. Source review describes what was read; it does not establish that a claim is true. Our research approach